Background--There is growing evidence that sleep duration and quality may be associated with cardiovascular harm and mortality.
C ardiovascular disease (CVD) causes over 787 000 deaths in the United States. 1 Whereas sleep duration is generally not considered a traditional risk factor for cardiovascular disease (CVD), growing evidence supports its association with cardiovascular risk (CVR) factors [2] [3] [4] [5] [6] [7] and disease, [8] [9] [10] [11] and quality of sleep appears to contribute to CVR. 10 ,12 Yet, current guidelines for the risk reduction of CVD make limited recommendations about quality or duration of sleep. 13, 14 The National Sleep Foundation recommends 7 to 9 hours of sleep for people aged 26 to 64 years and 7 to 8 hours of sleep for people aged ≥65 years, 14 and the Centers for Disease Control and Prevention has similar recommendations for adults. 15 Whether adults sleep the recommended hours is influenced by cultural, social, psychological, behavioral, pathophysiological, and environmental influences. 16, 17 Sleep duration may be reduced because of irregular working and shift-work patterns and round-the-clock availability of commodities of modern society. 18 However, guidelines make no specific reference with regard to sleeping beyond the recommended limit. Long sleep duration may be associated with obstructive sleep apnea, heart disease, and failing health 19 or may represent a symptom of early "latent" disease preceding a formal diagnosis. 20 Although previous reviews have evaluated sleep duration and mortality and cardiovascular outcomes, 10 ,16 these reviews have not quantified the CVR associated with each hour deviation below or above the recommended sleep duration. In addition, none of the previous reviews assessed the influence of sleep quality. 10, 16 Thus, we conducted a systematic review and meta-analysis of the impact of sleep duration and quality on CVD and mortality.
Methods
Data, analytical methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. The full methods, including detailed eligibility criteria, search strategy, data selection, extraction, and analysis, are reported in Data S1. The article was prepared according the guidance of the Meta-analysis of Observational Studies in Epidemiology (MOOSE) statement (Data S2).
Eligibility Criteria
We selected prospective cohort studies that reported on participants who quantified their duration of sleep or quality of sleep, and their association with subsequent CVD and mortality. The primary outcome was all-cause mortality, and secondary outcomes were CVD and mortality.
Search Strategy
We searched Medline and Embase using Ovid SP (from inception to the end of October 2015) using the search terms in Data S3.
Study Selection and Data Extraction
Two reviewers (C.S.K. and A.M.) checked all titles and abstracts for studies that could potentially meet the inclusion criteria. Data extraction and risk of bias assessment were performed independently by at least 2 reviewers (C.S.K., G.K., or M.G.). Publication bias was assessed using funnel plots.
Statistical Analysis
We used Stata software (version 14; StataCorpLP, College Station, TX) to perform regression analysis with randomeffects dose-response meta-analysis models to estimate the association between hours of sleep and adverse outcomes, using 7 hours of sleep as the reference category. The linear model represents the primary analysis, and the cubic model was included as a supplemental analysis.
Conventional random-effects meta-analysis was performed as a secondary analysis using RevMan 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). We decided to use random-effects models because they are more conservative compared with fixed-effect models, in the presence of any heterogeneity. Statistical heterogeneity was assessed using the I 2 statistic. The details of the main and sensitivity analyses are described in Data S1.
We also performed analysis of sleep quality (Data S4) in relation to mortality and cardiovascular outcomes.
Results

Description of Included Studies
A total of 74 studies met the inclusion criteria; the process of study selection is shown in Figure 1 . 8, 9, 11, 12, Study design and participant characteristics are shown in Table 1 .
The included studies were dated 1970-2017, which represented 3 340 684 participants. Among studies that reported crude events, there were 242 240 all-cause deaths in 2 564 029 participants from 44 studies (9.4%), 5435 coronary heart disease (CHD) deaths in 741 695 participants from
Clinical Perspective
What Is New?
• In this meta-analysis of 74 studies representing over 3 million participants, we found a J-shaped relationship between sleep duration and mortality and incident cardiovascular disease.
• Duration of sleep >8 hours of sleep was associated with increased risk of mortality.
• No significant effect was identified for periods of sleep <7 hours. Similar patterns were observed for stroke and cardiovascular disease mortality.
• Subjective poor sleep quality was associated with a significant increase in coronary heart disease, but not other outcomes.
What Are the Clinical Implications?
• Our study suggests that abnormal sleep is a marker of elevated cardiovascular risk.
• Future work should evaluate whether attention to optimizing the duration and quality of sleep may help reduce the burden of cardiovascular disease.
7 studies (0.7%), 6380 stroke deaths in 374 728 participants from 5 studies (1.7%), 32 988 cardiovascular deaths in 759 939 participants from 14 studies (4.3%), 32 084 CHD events in 540 538 participants from 14 studies (5.9%), 14 946 stroke events in 525 620 participants from 11 studies (2.8%), and 4160 CVD events in 97 832 participants from 6 studies (4.3%). Data S5 shows the prevalence of CVD and CVR factor profiles for each cohort.
Quality Assessment of Included Studies
The quality assessment is shown in Data S6. Studies used questionnaires or direct questioning to ascertain information about sleep quality or sleep duration. Methods used to estimate outcomes included population registries, death certification, questionnaires, and review of medical records or patient through interview or telephone call. Most studies adjusted for potential confounders, but the factors adjusted for varied across studies. Loss to follow-up was unclear in 30 studies, and 12 studies had 10% or more loss to follow-up or missing data. The study reference group and studies included for each analysis are shown in Data S7.
Sleep Duration and All-Cause Mortality
Numeric results of analyses are shown in Tables 2 and 3 . For the spline analysis, a total of 30 studies* reported data that could be used for the all-cause mortality analysis. When spline analysis was applied using a linear model, incremental deviation <7 hours of self-reported sleep was not associated with increased risk of allcause mortality, but sleep durations >8 hours were associated with increased risk of all-cause mortality ( Figure 2 ). The cubic spline analysis model is shown in Data S8. Pooled risk of all-cause mortality for the entire cohort ( Figure 2 , Data S9) and the subgroup of men and women only are shown in Data S10. There were a total of 39 studies included in the analysis.** The funnel plot for sleep duration and mortality did not suggest that there was publication bias. Deviation from self-reported sleep duration of 7 or 8 hours appeared to be associated with all-cause mortality, where longer sleep durations are associated with greater mortality compared with small increases for shorter durations. The similar J-shaped relationship was observed for the subgroup of men and women.
Sleep Duration and CHD Mortality and CHD
A total of 5 37,47,49,75,78 and 12*** studies were included in spline analysis for CHD mortality and CHD, respectively. Linear spline analysis failed to demonstrate any significant difference for both outcomes for self-reported shorter and longer sleep durations ( Figure 3 , cubic model in Data S8).
For the meta-analysis, there were 7 studies 37, 47, 49, 51, 61, 75, 78 (Data S11) and 15 studies**** (Data S12) for CHD mortality and CHD, respectively. Although there were fewer studies, a similar J-shaped pattern was observed where there was greater risk of CHD mortality and events with incremental deviation from the reference 7 to 8 hours of self-reported sleep (a modest increase for 6 hours and greater increase for ≤5 hours; Data S10). The funnel plot for self-reported sleep duration and CHD mortality suggested a possible publication bias whereas for CHD the plot did not suggest that there was a publication bias.
Sleep Duration and Stroke Mortality and Stroke
Linear spline analysis for stroke mortality and stroke included 3 47 There was no difference in stroke events associated with self-reported sleep duration shorter or longer than 7 hours, but a moderate increase in stroke mortality if sleep duration was >7 hours ( Figure 3 , Data S8). Meta-analysis of 5 studies 27, 47, 49, 51, 65 were included in the analysis of stroke mortality (Data S10). For stroke events, there were 13 studies. † The funnel plot for sleep duration and stroke mortality did not suggest a publication bias. For stroke mortality, there appeared to be no difference in events with self-reported sleep duration <7 hours, but significant and moderate increase in events with longer sleep duration >8 hours (Data S13). However, for stroke events, the increase in event rates are preserved for both sleep duration <7 hours (modest for 6 hours and a greater increase for ≤5 hours) and a moderate increase for >8 hours (Data S14). The funnel plot for sleep duration and stroke did not suggest a publication bias.
Sleep Duration and Cardiovascular Mortality and CVD
Spline analysis using linear models did not shown any difference in events with shorter duration than 7 hours for both cardiovascular mortality (8 studies) 11, 25, 44, 47, 49, 71, 87, 88 and CVD (7 studies). 8, 12, 22, 33, 38, 42, 74 However, longer selfreported sleep duration >7 hours appeared to be associated with a moderate increase in greater stroke mortality (cubic model shown in Data S8). There were 16 studies ‡ (Data S15) that evaluated CVD mortality and 8 studies 8, 12, 22, 28, 33, 38, 42, 74 (Data S16) that evaluated CVD events. The J-shaped pattern was observed for self-reported sleep duration and CVD mortality, but this was not the case for CVD events, but there were fewer studies in the event analysis. The funnel plot for sleep duration and CVD mortality and CVD did not suggest a publication bias. Incremental decrease in hours of sleep was associated with significant increase in mortality (Data S10).
Sleep Quality and Mortality and Adverse Cardiovascular Outcomes
A total of 17 studies § were included in the analysis of subjective sleep quality and adverse outcomes (Data S10 and Data S17). For all-cause mortality, there were 12 652 deaths Sensitivity analysis was performed on the meta-analysis data (Data S18). After exclusion of studies that included participants with baseline CVD, there was a significant increase in all-cause mortality with longer and shorter self-reported hours of sleep (small for 6 hours, modest for 5 and 9 hours, and moderate for 4 and 10 hours) and moderate increase in CVD mortality and stroke mortality with longer hours of sleep. Similar observations were found for studies that adjusted for CVR factors. For the analysis of CHD and stroke, there were significant and moderate increases in events when baseline CVD was excluded with 5-hour duration of sleep. For the adjustments for obstructive sleep apnea analysis, some of the results were no longer statistically significant because there were fewer studies.
Discussion
In this meta-analysis of 60 studies representing over 3 million participants, we observed that divergence from the recommended 7 to 8 hours of sleep was significantly associated with a moderate increase in mortality and incident CVD. We observed a J-shaped relationship between sleep duration and mortality, and incident adverse cardiovascular events were observed. When spline analysis was applied to evaluate the incremental association of sleep duration and adverse events, our results suggest that longer than the recommended duration of 7 to 8 hours of sleep may be associated with a moderate degree of harm, compared with those who slept for durations shorter than that recommended.
Our study provides evidence that may contribute to important clinical and public health messages. First, we observed through spline analysis a more-precise estimation of the risk gradient of CVD and mortality on the greater side of the recommended 7 to 8 hours of sleep compared to existing studies. Second, deviations in sleep duration and quality may be a nonspecific marker for increased CVR that might warrant determination of CVR. In particular, clinicians may need to be aware that the risk gradient appears to be aHR indicates adjusted hazard ratio; aOR, adjusted odds ratio; aRR, adjusted risk ratio; CHD, coronary heart disease; CVD, cardiovascular disease; IHD, ischemic heart disease; MI, myocardial infarction; PSQI, Pittsburgh Sleep Quality Index. Sleep duration and all-cause mortality in men: <6 h: aRR 1.1 (0.6-7.0), 7 to 8 h: aRR 1.00, >8 h: aRR 2.0 (1.2-3.2). Sleep duration and all-cause mortality in women: <6 h: aRR 1.0 (0.6 -1.8), 7 to 8 h: aRR 1.00, >8 h: aRR 1.3 (0.6-2.6). Sleep duration and coronary artery disease mortality in men: <6 h: aRR 0.7 (0.3-1.7), 7 to 8 h: aRR 1.00, >8 h: aRR 2.2 (1.0-4.4). Sleep duration and coronary artery disease mortality in women: <6 h: aRR 1.2 (0.4-4.2), 7 to 8 h: aRR 1.00, >8 h: aRR 0.7 (0.1-5.2). Poor sleep quality (difficulty maintaining sleep) and all-cause mortality in men: aRR 1.4 (1.1-1.9). Poor sleep quality (difficulty maintaining sleep) and coronary artery disease mortality in men: aRR 1.2 (0.7-1.9). Poor sleep quality (difficulty maintaining sleep) and all-cause mortality in women: aRR 1.1 (0.7-1.7). Poor sleep quality (difficulty maintaining sleep) and coronary artery disease mortality in women: aRR 1.1 (0.5-2.9). steeper for long sleep duration compared with short duration, so individuals with excessive sleeping patterns may warrant further clinical assessment. Third, we provide updated evidence that supports the J-shaped relationship where longer sleep is associated with significantly higher mortality and CVD and further the knowledge by highlighting that excess sleep is possibly associated with a greater likelihood of harm than less sleep with spline analysis. In addition, we found that sleep quality emerged as an important risk factor for CHD, so clinicians should consider nonrestorative sleep (or "waking up unrefreshed") during patient assessment. Finally, our study highlights current evidence that sleep may be an important factor for individuals who wish to adopt a healthier lifestyle-our findings support public health campaigns promoting good sleep practices and behaviors and the importance of the clinician discussing sleep in primary care consultations. St-Onge et al recently published a scientific statement on behalf of the American Heart Association. 91 Their review surveyed the literature and found that sleep duration, mostly short sleep, and sleep disorders are related to adverse cardiometabolic risk, such as obesity, hypertension, type 2 diabetes mellitus, and CVD. Unlike their review, we focused on mortality and CVD and quantitatively pooled the impact of individual hours of sleep duration and these events. We were able to show, with metaregression, that the association of short sleep duration and adverse events was lost, but the association of long sleep duration and adverse events still persists. It is possible that the adverse outcomes associated with short sleep duration may be manifested through the risk factors described by St-Onge's review. Our findings support the clinical recommendations of the American Heart Association, in which sleep behaviors should be addressed to promote cardiac health, and public health campaigns addressing sleep behavior should include explicit guidelines for adequate sleep.
Our meta-analysis results show a possible increase in mortality with both long and short duration of sleep relative to 7 or 8 hours, but after spline analysis, there is no difference in mortality for patients with shorter sleep duration. The spline regression is the gold standard for metaregression for nonlinear relationships to model exposures and outcomes. We further used this method to perform analysis on the subgroups studies that had more-complete reporting that include crude event rates.
The exact mechanisms that underlie the association between sleep and CVD and mortality are not fully understood. Short sleep duration has been shown to increase levels of leptin and ghrelin, 92, 93 which leads to increased appetite, caloric intake, reduce energy expenditure, and facilitates the development of obesity 80 and impaired glycemic control. 94 Cortisol also increases with reduced sleep, and altered growth hormone metabolism may increase CVR. 95 Low-grade inflammation occurs with reduced sleep, which may be associated with CVD and cancer. Long sleep duration may be associated with an increased risk of CVD because of an adverse CVR factor profile or prevalent comorbidities that lead to fatigue, such as chronic inflammatory disorders and anemia. Depressive symptoms, low socioeconomic status, unemployment, and low physical activity are also associated with long sleep duration, which may confound the association of long sleep with morbidity and mortality. An important consideration in the temporal relationship between sleep and adverse outcomes is the potential influence of CVR factors. For example, a Japanese study observed that sleep disturbances were associated with a higher risk of later-onset of type 2 diabetes mellitus. 96 In addition, it is unclear whether abnormal sleep is a marker of SYSTEMATIC REVIEW AND META-ANALYSIS undiagnosed prevalent CVDs or of early/latent disease that subsequently manifests in adverse cardiovascular outcomes and death. Some studies have attempted to reduce the effect of baseline prevalent CVD by excluding patients with these conditions whereas other studies adjusted for these factors. Despite our sensitivity analysis considering exclusion D, Stroke (15 studies). E, CVD mortality (11 studies). F, CVD (8 studies). CHD indicates coronary heart disease; CVD, cardiovascular disease.
and adjustments, there may still be residual confounding given that there may be undiagnosed or latent disease or risk factors because some of these population-based studies do investigate patients at baseline for these variables and rely on self-reporting. The other important consideration is whether the increased incident CVR is causally related to sleep directly or whether abnormal sleep patterns may contribute to adverse health behaviors that increase CVR thereby contributing to the increase in cardiovascular events. Several studies have evaluated the mismatch between selfreported sleep and more-objective measures. An analysis of 669 participants in the CARDIA (Coronary Artery Risk Development in Young Adults) Sleep Study suggests a moderate correlation between self-reported and objectively measured sleep duration with evidence of systematic errors in the mean and calibration. 97 Another study of 2086 Hispanic
Americans suggests a moderate correlation between selfreported sleep and actigraphy results. 98 A smaller study that compared self-reported sleep and actigraphy in 56 participants reported a poor agreement between sleep duration and quality, as assessed by a questionnaire and objectively measured sleep. 99 In addition, a different analysis of 63 patients who were overweight and obese individuals and who underwent actigraphy also reported a weak correlation between usual sleep time and actigraph estimates. 100 With respect to CVR, studies suggest that self-reported sleep duration is different from objectively assess sleep duration. 101, 102 Although the exact reasons for discrepancies between subjective and objective measures are not clear, it appears that self-reported sleep is only, at best, moderately correlated with objective measures of sleep and perhaps multiple measures of sleep duration should be recommended for future studies.
In the current analysis, the study by Kripke et al 53 represented more than one third of the entire cohort, and this large study has implications to the interpretation of the results. This cohort was a diverse group of adults who were friends or relatives of American of Cancer Society volunteers who were aged between 30 and 102 years. The mean age in this study was 57 years and 43% of participants were female, which were both slightly lower than the average of 60 years of age and 52% female in all the included studies. In addition, the study took place in the 1980s, which may affect the applicability of its findings to the current population. Collectively, these findings may limit the generalizability of the current study. Our study has a number of limitations. Although we used adjusted estimates where available, there are likely to be residual or unmeasured confounding and bias. For example, an underlying physical or mental health condition may be the driver behind extreme sleep patterns. A key limitation was that sleep duration was assessed by self-reported questionnaires. It is unclear whether this is truly reflective of actual sleep patterns given that there are studies that clearly show that with respect to CVR, self-reported sleep duration and objectively assessed sleep duration are significantly different. 101, 102 Another limitation was the absence of individual patient-level data, so we could not make assumptions about the CVR factor profiles of patients based on their sleep duration or quality. Some studies did report baseline risk factors for patients, but every study reported different risk factors, and the combinations of the risk-factor profiles reported were too heterogeneous to make general assumptions. Although we demonstrated an association between sleep quality, duration, and outcomes, these relationships cannot infer causality and it is unclear whether sleep duration or quality is a marker of prevalent CVR, an adverse CVR factor profile, or adverse health behaviors that contribute to the adverse outcomes reported.
Conclusion
In conclusion, we found a significant association between deviations in sleep duration and both mortality and adverse cardiovascular outcomes. National guidelines should consider advocating this as the recommended sleep duration. We also found evidence that sleep duration above the recommended level of 7 to 8 hours was associated with a moderate degree of harm compared with sleeping less than the suggested duration. Furthermore, the greater the divergence from the recommended durations of sleep, the greater the association for cardiovascular harm and mortality. Our study suggests that abnormal sleep is a marker of elevated CVR-and greater consideration should be given in exploring during patient consultations in both the duration and quality of sleep.
